K-V Pharmaceutical Co. has adopted a new corporate name, Lumara Health Inc.


K-V Pharmaceutical, new corporate name, Lumara Health, women's health, maternal health, Makena, hydroxyprogesterone caproate injection, women's health care division, Greg Divis, Joseph Mahady


































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

K-V Pharmaceutical changes name to Lumara Health

May 30th, 2014

ST. LOUIS – K-V Pharmaceutical Co. has adopted a new corporate name, Lumara Health Inc.

The specialty pharmaceutical company said Thursday that the new name reflects changes that it has has made since emerging from Chapter 11 bankruptcy protection last year to sharpen its focus on women's health.

"With new ownership, a new board of directors with a strong and diverse background in health care, new members of our leadership team who bring deep expertise that complement our current capabilities, and the recapitalization of our finances, we are in a stronger position today to deliver on our core mission," stated Greg Divis, chief executive officer of Lumara Health. "We're excited about the direction the company is headed and our ability to contribute to advancements in women's healthcare."

Based in St. Louis, Lumara Health aims to advance the health of women throughout the stages of their lives, with a particular focus on maternal health. As part of a recent reorganization of its operations, the company created a maternal health division, which specializes in addressing preterm birth.

Lumara said its flagship product, Makena (hydroxyprogesterone caproate injection), is the only Food and Drug Administration-approved product to reduce the risk of recurrent preterm birth in certain at-risk women. Since Makena's approval by the FDA, tens of thousands of these patients have been prescribed Makena to help reduce their risk for recurrent preterm birth.

"Whether it's a new partnership to provide patients and healthcare providers the option of home administration of Makena, or spearheading the largest randomized controlled trial to date assessing the impact of progestogen therapy, there are good things happening within the company," commented Joseph Mahady, who was appointed chairman of Lumara's board last October.

Lumara has also formed a women's health care division. The company's FDA-approved products in this division help treat a number of women's health issues, including vaginal infections and menopausal symptoms.

"The company's recent reorganization demonstrates its focus on maternal health as a core element of its contribution to the women's health care space," stated Roger Newman, M.D., professor and Maas Chair for reproductive sciences in the department of obstetrics and gynecology at the Medical University of South Carolina. "The new leadership of the company speaks to the commitment they have towards positively shaping the future of women's health, particularly in preterm birth."

Advertisement